Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[EX Q]: Paragraph: After more than three hours of debate, lawmakers in parliament's upper house voted on Tuesday for a change in the law to allow the treatments, echoing a positive vote in the lower house earlier this month. The treatment, called mitochondrial transfer, is known as "three-parent" in vitro fertilization (IVF) because the babies, born from genetically modified embryos, would have DNA from a mother, a father and from a female donor. Although the techniques are still at the research stage in laboratories in Britain and the United States, experts say that now legal hurdles have been overcome, Britain's first 3-parent baby could be born as early as 2016. Mitochondrial transfer involves intervening in the fertilization process to remove faulty mitochondrial DNA, which can cause inherited conditions such as heart problems, liver failure, brain disorders, blindness and muscular dystrophy. Mitochondria act as tiny energy-generating batteries inside cells, and around 1 in 6,000 babies around the world are born with serious mitochondrial disorders. Responding to the vote, Jeremy Farrar, director of the Wellcome Trust medical charity commended lawmakers for a "considered and compassionate decision". "Families who know what it is like to care for a child with a devastating disease are the people best placed to decide whether mitochondrial donation is the right option," he said. Mark Downs, chief executive of the Society of Biology, hailed "a great day for UK science" and said the landmark decision "will ensure mothers who carry faulty mitochondria can have healthy children free from the devastating conditions." But Marcy Darnovsky, director of the campaign group The Center for Genetics and Society, called the move a "historic mistake" which turns children into biological experiments and will "forever alter the human germline". "The techniques ... are relatively crude and will not in and of themselves create so-called designer babies," she said. "However, they will result in children with DNA from three different people in every cell of their bodies, which will impact a large range of traits in unknowable ways and introduce genetic changes that will be passed down to future generations." Claim: Britain becomes first nation to legalize three-parent babies.
[EX A]: - Britain will become the first nation to legalize a "three-parent" IVF technique which doctors say can prevent some inherited incurable diseases but which critics fear will effectively lead to "designer babies".

[EX Q]: Paragraph: Sen. Charles Schumer of New York said the VA needs to provide Congress more information about a recent bulk order for $208,000 worth of hydroxychloroquine. President Donald Trump has heavily promoted the malaria drug, without evidence, as a treatment for COVID-19. Schumer's request comes after a whistleblower complaint filed this past week by former Health and Human Services official Rick Bright alleged that the Trump administration, eager for a quick fix to the onslaught of the coronavirus, wanted to "flood" hot spots in New York and New Jersey with the drug. Major veterans organizations have urged VA to explain under what circumstances VA doctors initiate discussion of hydroxychloroquine with veterans as a treatment option. "There are concerns that they are using this drug when the medical evidence says it doesn't help and could hurt," Schumer said in an interview with The Associated Press. He said given the fact the malaria drug, despite being untested, had been repeatedly pushed publicly by Trump, VA Secretary Robert Wilkie must address whether anyone at the department was pressured by the White House or the administration to use hydroxychloroquine for COVID-19. Schumer said Wilkie also should answer questions about a recent analysis of VA hospital data that showed there were more deaths among patients given hydroxychloroquine versus standard care, including how much patients knew about the drug's risks before taking it. In a statement Sunday, VA spokeswoman Christina Noel called it "preposterous" for anyone to suggest that VA would make treatment decisions based on anything other than "the best medical interests of patients." "VA only permits use of the drug after ensuring veterans and caretakers are aware of potential risks associated with it, as we do with any other drug or treatment," she said. Wilkie in recent weeks has denied that veterans were used as test subjects for the drug and that it was instead administered at government-run VA hospitals only when medically appropriate, with mutual consent between doctor and patient. Still, Wilkie and the department have repeatedly declined to say how widely the drug was being used for COVID-19, including how many veterans were given the drug, and whether VA doctors were given guidance by VA headquarters on specific scenarios when it should be used. In a weekly call with veterans' groups this past week, Wilkie continued to defend VA's use of hydroxychloroquine. He dismissed the recent analysis of VA hospital data showing no benefits to patients, suggesting the poor outcomes were because the cases involved older, very sick veterans. "Use of this medication for treatment of COVID-19 is considered 'off label' perfectly legal and not rare," he wrote in an April 29 letter to veterans' groups. The analysis of hospital data, done by independent researchers at two universities with VA approval, was not a rigorous experiment. Researchers analyzed medical records of 368 older male veterans hospitalized with confirmed coronavirus infection at VA medical centers who died or were discharged by April 11. About 28% of veterans who were given hydroxychloroquine plus usual care died, versus 11% of those getting routine care alone. The VA recently said most of its recent bulk order for hydroxychloroquine was being used for approved uses, such as treating lupus and rheumatoid arthritis, but it didn't provide breakdowns. Wilkie in recent weeks took advocacy of the drug even further than Trump by claiming without evidence that it has been effective for young and middle-aged veterans in particular. In fact, there is no published evidence showing that. Veterans are "very concerned that we still do not have clarity on the VA's past and present use of hydroxychloroquine in treating veterans with COVID-19," Jeremy Butler, chief executive officer of Iraq and Afghanistan Veterans of America, told the AP. "Now that the federal government issued an emergency use authorization for remdesivir to treat COVID-19, we need answers to these questions as well as the VA's plans for administering, or not administering, remdesivir," he said. That action by the Food and Drug Administration came after preliminary results from a government-sponsored study showed that remdesivir shortened the time to recovery by 31%, or about four days on average, for hospitalized COVID-19 patients. In a tweet Sunday, former VA Secretary David Shulkin urged the department to immediately curtail use of hydroxychloroquine for COVID-19. "With studies showing no benefit, VA should restrict use exclusively to clinical trials," he wrote. Shulkin was fired by Trump in March 2018, and Wilkie replaced him. Schumer said his main concern is determining whether the VA had conducted any "clandestine studies to determine whether hydroxychloroquine was effective without their permission." He said there's also concern that the department won't address specifically where the drug was sent. "These are people who risked their lives for us," Schumer said. "They should be treated only with the utmost dignity, respect and high standards of care." The drug has long been used to treat malaria and other ailments. A few, very small preliminary studies suggested it might help prevent the coronavirus from entering cells and possibly help patients clear the virus sooner. But the FDA last month warned doctors against prescribing the drug for COVID-19 outside hospitals because of the risks of serious side effects and death. Claim: Schumer calls on VA to explain use of unproven drug on vets.
[EX A]: The Senate's top Democrat on Sunday called on the Department of Veterans Affairs to explain why it allowed the use of an unproven drug on veterans for the coronavirus, saying patients may have been put at unnecessary risk.

[EX Q]: Paragraph: Such a test could initially be used to select patients for clinical trials of experimental treatments being developed to try to halt progression of Alzheimer's, the researchers said, and may one day move into routine use in doctors' clinics. "Alzheimer's begins to affect the brain many years before patients are diagnosed (and) many of our drug trials fail because by the time patients are given the drugs the brain has already been too severely affected," said Simon Lovestone of Oxford University, who led this work from King's College London. "A simple blood test could help us identify patients at a much earlier stage to take part in new trials and hopefully develop treatments," he said. Alzheimer's is the most common form of dementia, a brain-wasting disease which in 2010 was estimated to be costing the world $604 billion a year. The fatal disease affects 44 million people worldwide, with the number set to triple by 2050, the campaign group Alzheimer's Disease International says. Several big pharma firms including Roche, Eli Lilly, Merck & Co and Johnson & Johnson, are pursuing various approaches to get to the root cause of Alzheimer's and try to find treatments to halt its progression. Yet over the past 15 years, more than 100 experimental Alzheimer's drugs have failed in trial. Lovestone and other experts believe this may be because drug trials are conducted too late, in patients whose condition has already gone too far. A predictive test for use before people develop symptoms would help researchers select the right people for drug trials, and help show whether the experimental drugs are working. Previous studies have found that PET brain scans and tests of lumbar fluid can be used to predict the onset of dementia from people with a less severe condition known as mild cognitive impairment (MCI), but these tests are expensive and invasive, so scientists are keen to develop a cheaper, simpler blood test. MCI includes problems with day-to-day memory, language and attention. It can be an early sign of dementia, or a symptom of stress or anxiety. Around 10 percent of people diagnosed with MCI develop dementia within a year. Apart from regular assessments to measure memory decline, there is currently no accurate way of predicting who will or won't develop dementia. For this study, published in the journal Alzheimer's & Dementia, Lovestone's team used blood samples from 1,148 people - 476 with Alzheimer's, 220 with mild cognitive impairment and 452 elderly controls without dementia. They were analyzed for 26 proteins previously found to be linked with Alzheimer's. The team found 16 of these 26 proteins to be strongly associated with brain shrinkage in either MCI or Alzheimer's and then ran a second series of tests to see which of these could predict which patients would progress from MCI to Alzheimer's. With this second series, they found a combination of 10 proteins capable of predicting with 87 percent accuracy whether people with MCI would develop Alzheimer's disease within a year. Experts in the field welcomed the results but said they should be replicated in larger studies before an Alzheimer's blood test could be rolled out for use in doctors' clinics. "The results reported today are interesting, but as the authors point out there is still a very large amount of work remaining until a usable blood test for Alzheimer's disease becomes available," said Adrian Pini of the MRC Center for Developmental Neurobiology at King's College London. James Pickett, head of research at the Alzheimer's Society, said the research "does not mean that a blood test for dementia is just around the corner". "These 10 proteins can predict conversion to dementia with less than 90 percent accuracy, meaning one in 10 people would get an incorrect result," he said. "Accuracy would need to be improved before it could be a useful diagnostic test." Claim: Study paves the way for a blood test to predict Alzheimer's.
[EX A]:
British scientists have identified a set of 10 proteins in the blood that can predict the onset of Alzheimer's and call this an important step towards developing a test for the incurable brain-wasting disease.